Sign In
Buy ACXP
$1.75
-0.0500 (-2.78%)
At Close: Jun 03, 2026
Acurx Pharmaceuticals, Inc. Announces Reverse Stock Split
09:25am, Thursday, 31'st Jul 2025
Acurx's common stock is expected to begin trading on a post-split adjusted basis on August 5, 2025 STATEN ISLAND, N.Y. , July 31, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acur
Acurx Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 12, 2025 Conference Call and Provide Business Update
07:01am, Thursday, 24'th Jul 2025
STATEN ISLAND, N.Y. , July 24, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiot
Are Medical Stocks Lagging Acurx Pharmaceuticals (ACXP) This Year?
10:41am, Wednesday, 18'th Jun 2025
Here is how Acurx Pharmaceuticals, Inc. (ACXP) and BioCryst Pharmaceuticals (BCRX) have performed compared to their sector so far this year.
Acurx Pharmaceuticals, Inc. Announces Exercise of Warrants for $2.67 Million Gross Proceeds
09:47pm, Tuesday, 17'th Jun 2025
STATEN ISLAND, N.Y. , June 17, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics
Acurx Announces Publication in Lancet Microbe of Phase 2b Clinical Trial Data for Ibezapolstat in CDI
07:01am, Tuesday, 17'th Jun 2025
As previously reported, 15 out of 16 (94%) patients in Phase 2b in the Per Protocol Population experienced Clinical Cure (CC) and all 15 of 15 (100%) remained free of C. difficile infection (CDI) re
Results are from Acurx's ongoing scientific collaboration with Leiden University Medical Center (LUMC) partially under a grant from Health Holland to further study the mechanism of action of DNA pol
Acurx Pharmaceuticals, Inc. (ACXP) Q1 2025 Earnings Call Transcript
01:59pm, Tuesday, 13'th May 2025
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Robert Shawah - Co-Founder and CFO David Luci - President and CEO Conference Ca
Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update
07:01am, Tuesday, 13'th May 2025
STATEN ISLAND, N.Y. , May 13, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics
Acurx Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 13, 2025 Conference Call and Provide Business Update
07:30am, Wednesday, 30'th Apr 2025
STATEN ISLAND, N.Y. , April 30, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibi
Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
07:30am, Monday, 28'th Apr 2025
STATEN ISLAND, N.Y. , April 28, 2025 /PRNewswire/ -- Acurx Pharmaceuticals (Nasdaq: ACXP) (Acurx or the Company), a late-stage biopharmaceutical company developing a new class of small molecule antibi
Indian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors
07:30am, Thursday, 17'th Apr 2025
STATEN ISLAND, N.Y. , April 17, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molec
Acurx Pharmaceuticals (ACXP) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
10:55am, Tuesday, 08'th Apr 2025
After losing some value lately, a hammer chart pattern has been formed for Acurx Pharmaceuticals (ACXP), indicating that the stock has found support. This, combined with an upward trend in earnings es
Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's What You Should Know
01:01pm, Friday, 21'st Mar 2025
Acurx Pharmaceuticals (ACXP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Acurx Pharmaceuticals, Inc. (ACXP) Q4 2024 Earnings Call Transcript
09:44am, Tuesday, 18'th Mar 2025
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q4 2024 Earnings Conference Call March 18, 2025 8:00 AM ET Company Participants Robert Shawah - Co-Founder and Chief Financial Officer David Luci - President
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
07:01am, Tuesday, 18'th Mar 2025
STATEN ISLAND, N.Y. , March 18, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibi
